Atezolizumab & Bevacizumab

DRUG7 trials

Conditions

DownstagingHepato Cellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)Liver Transplant SurgeryMacrovascular InvasionMesothelioma, MalignantVenous Thrombosis

Phase 1

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

RecruitingNCT06725121

University Health Network, TorontoDownstaging, Hepatocellular Carcinoma (HCC), Liver Transplant Surgery +1

Start: 2024-12-31End: 2034-06-30Target: 48Updated: 2024-12-16

Phase 2

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

NCT03654833

University of LeicesterMesothelioma, Malignant

Start: 2019-01-28End: 2023-10-31Updated: 2023-03-14

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

RecruitingNCT07192185

Sun Yat-sen UniversityHepatocellular Carcinoma (HCC)

Start: 2025-09-17End: 2027-03-01Target: 30Updated: 2025-09-25

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

RecruitingNCT07276100

IRCCS Azienda Ospedaliero-Universitaria di BolognaHepato Cellular Carcinoma (HCC)

Start: 2026-01-01End: 2029-01-01Target: 15Updated: 2025-12-10

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

RecruitingNCT07293468

Tuen Mun HospitalHepatocellular Carcinoma (HCC)

Start: 2024-04-01End: 2034-12-31Target: 106Updated: 2025-12-19

Phase 3

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruitingNCT04649489

Jia FanVenous Thrombosis

Start: 2021-04-19End: 2028-03-31Target: 501Updated: 2026-01-15

Unknown Phase

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

CompletedNCT07272265

Sun Yat-sen UniversityHepatocellular Carcinoma (HCC)

Start: 2020-10-28End: 2025-11-10Updated: 2025-12-09

2025-10-07

Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy.

Journal of Clinical Oncology2025-05-28

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

BMJ Oncology2024-12-012 citations

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

2024-08-2119 citations

The treatment outcomes of patients who failed to be randomly assigned after atezo/bev induction therapy in the Chinese TALENTop study.

Journal of Clinical Oncology2024-06-011 citations

The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.

Journal of Clinical Oncology2024-06-011 citations

Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.

Journal of Clinical Oncology2024-06-01

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort

ERJ Open Research2023-11-017 citations

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

BMJ Open2023-11-014 citations

Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.

Journal of Clinical Oncology2023-06-016 citations

A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.

Journal of Clinical Oncology2023-06-011 citations

28P Epithelial mesenchymal transition confers resistance to dual PDL1-VEGF inhibition in relapsed mesothelioma

Immuno-Oncology Technology2022-12-01

TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.

Journal of Clinical Oncology2022-06-019 citations

Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy.

Journal of Clinical Oncology2022-06-011 citations

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

2022-02-1149 citations

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

Journal of Clinical Oncology2021-05-207 citations

Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

2021-01-2775 citations

MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.

Journal of Clinical Oncology2020-05-205 citations